Suspected non-Alzheimer disease pathophysiology — concept and controversy
- 18 January 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Neurology
- Vol. 12 (2), 117-124
- https://doi.org/10.1038/nrneurol.2015.251
Abstract
Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in whom biomarkers of neurodegeneration are abnormal. Clinically normal and mildly impaired individuals with SNAP are at increased risk of poor clinical and cognitive outcomes. In this Perspectives article, Clifford Jack and colleagues describe the available data on SNAP and address topical controversies in the field. Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in whom biomarkers of neurodegeneration are abnormal. The term SNAP has been applied to clinically normal individuals (who do not meet criteria for either mild cognitive impairment or dementia) and to individuals with mild cognitive impairment, but is applicable to any amyloid-negative, neurodegeneration-positive individual regardless of clinical status, except when the pathology underlying neurodegeneration can be reliably inferred from the clinical presentation. SNAP is present in ∼23% of clinically normal individuals aged >65 years and in ∼25% of mildly cognitively impaired individuals. APOE*ε4 is underrepresented in individuals with SNAP compared with amyloid-positive individuals. Clinically normal and mildly impaired individuals with SNAP have worse clinical and/or cognitive outcomes than individuals with normal levels of neurodegeneration and amyloid-β biomarkers. In this Perspectives article, we describe the available data on SNAP and address topical controversies in the field.Keywords
This publication has 97 references indexed in Scilit:
- Evidence for Ordering of Alzheimer Disease BiomarkersArchives of Neurology, 2011
- National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approachActa Neuropathologica, 2011
- An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer diseaseAnnals of Neurology, 2011
- Ecology of the Aging Human BrainArchives of Neurology, 2011
- Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studiesActa Neuropathologica, 2011
- Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer diseaseAnnals of Neurology, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without DementiaNeuron, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controlsHuman Brain Mapping, 2009